

<b>Examiner-Initiated Interview Summary</b>	Application No.	Applicant(s)	
	10/800,253	BROWN ET AL.	
	Examiner	Art Unit	
	Jason M. Nolan, Ph.D.	1626	

**All Participants:**

(1) Jason M. Nolan, Ph.D.

(2) Phil Polster.

**Status of Application:** \_\_\_\_\_

(3) \_\_\_\_\_

(4) \_\_\_\_\_

**Date of Interview:** 13 February 2006

**Time:** 4:30 PM

**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

**Exhibit Shown or Demonstrated:** ☐ Yes ☐ No

If Yes, provide a brief description: \_\_\_\_\_

**Part I.**

Rejection(s) discussed:

Claims discussed:

36-37 & 44-46

Prior art documents discussed:

**Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

*See Continuation Sheet*

**Part III.**

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed:

1. In Claim 36, page 15, line 2, after "in a mammal" and before ", said method. . ." insert - - selected from the group consisting of asthma, chronic bronchoconstriction, acute bronchoconstriction, chronic bronchitis, small airways obstruction, emphysema, obstructive or inflammatory airways diseases, pneumoconiosis, bronchitis, and bronchiectasis - -.
2. Delete Claims 37 and 44-46.
3. In Claim 48, page 17, line 11, after "NR9R10;" and before "and R9 and R10 are" insert - - Ra is a (C1-C4)alkyl; - -.
4. Submit a Terminal Disclaimer for US Patent 6,844,362.